Astria Therapeutics (ATXS) Company Report

Astria Therapeutics, Inc. stockholders voted to approve the acquisition of Astria by BioCryst Pharmaceuticals, Inc. at a special meeting held on January 21, 2026.
The merger is expected to close on or about January 23, 2026, pending the satisfaction of customary closing conditions.

Jan 21, 2026, 9:00 PM

Press Release

Astria Therapeutics Reports Q3 2025 Results and BioCryst Acquisition Details

ATXS

Earnings

M&A

New Projects/Investments

Astria Therapeutics, Inc. reported a net loss of $31.6 million for the third quarter ended September 30, 2025, compared to a net loss of $24.5 million for the same period in 2024, with collaboration revenue of $0.7 million.
On October 14, 2025, BioCryst Pharmaceuticals, Inc. announced its intent to acquire Astria for $8.55 in cash and 0.59 shares of BioCryst common stock per share, with the transaction expected to close in the first quarter of 2026.
The company held $227.7 million in cash, cash equivalents, and short-term investments as of September 30, 2025, and anticipates this will fund operations into 2028.
Topline results for the Phase 3 ALPHA-ORBIT trial of navenibart are expected in early 2027, and Astria received a $16 million upfront payment in Q4 2025 from Kaken Pharmaceutical for licensing navenibart in Japan.

Nov 12, 2025, 1:07 PM

8-K

Astria Therapeutics Reports Q3 2025 Financial Results and BioCryst Acquisition Update

ATXS

Earnings

M&A

New Projects/Investments

Astria Therapeutics reported a net loss of $31.6 million or $0.55 per share for the third quarter ended September 30, 2025, with $227.7 million in cash, cash equivalents, and short-term investments as of that date.
BioCryst Pharmaceuticals is expected to acquire Astria in the first quarter of 2026 for $8.55 in cash and 0.59 shares of BioCryst common stock per share.
The Phase 3 ALPHA-ORBIT trial for navenibart is progressing, with topline results anticipated in early 2027, following final Phase 1b/2 ALPHA-STAR results showing an 84–92% mean reduction in HAE attack rate.
Initial Phase 1a data for STAR-0310 demonstrated a best-in-class half-life of up to 68 days, and the company is exploring strategic opportunities for the program.

Nov 12, 2025, 1:00 PM

Press Release

Astria Therapeutics Announces Positive Final Results for Navenibart ALPHA-STAR Phase 1b/2 Trial

ATXS

New Projects/Investments

Astria Therapeutics announced final positive results from the full enrollment group of 29 patients in the ALPHA-STAR Phase 1b/2 clinical trial for navenibart (STAR-0215) in hereditary angioedema (HAE) patients.
The trial demonstrated robust attack rate reduction, a favorable safety and tolerability profile, and supports potential for infrequent dosing (every three-month and every six-month regimens).
Efficacy data showed mean/median attack rate reductions from baseline through six months of treatment ranging from 84% / 93% to 92% / 100% across cohorts.
Navenibart was generally well-tolerated with no serious treatment-emergent adverse events, and all 29 patients (100%) elected to continue treatment in a long-term open-label trial.
The Phase 3 ALPHA-ORBIT trial for navenibart is progressing as planned, with topline results anticipated in early 2027.

Nov 6, 2025, 1:00 PM

Press Release

Astria Therapeutics to be Acquired by BioCryst Pharmaceuticals

ATXS

M&A

Takeover Bid

Board Change

BioCryst Pharmaceuticals has agreed to acquire Astria Therapeutics for approximately $700 million, with Astria shareholders receiving $8.55 in cash plus 0.59 shares of BioCryst common stock for each Astria share, representing a 53-54% premium.
The transaction, expected to close in Q1 2026, will integrate Astria's lead product, navenibart (for hereditary angioedema prevention), into BioCryst's portfolio and result in Astria's delisting from Nasdaq.
The acquisition will be financed using BioCryst's cash reserves and a new $550 million financing facility with Blackstone.
Astria's CEO, Jill Milne, will join BioCryst's board of directors after the acquisition is completed.

Oct 14, 2025, 11:16 AM

Morningstar

Astria Therapeutics to be Acquired by BioCryst Pharmaceuticals

ATXS

M&A

New Projects/Investments

Board Change

BioCryst Pharmaceuticals, Inc. has agreed to acquire Astria Therapeutics, Inc. for an implied value of $13.00 per share, consisting of $8.55 in cash and 0.59 shares of BioCryst common stock, representing an implied enterprise value of approximately $700 million.
The acquisition, expected to close in the first quarter of 2026, will add navenibart, a late-stage plasma kallikrein inhibitor in Phase 3 clinical development for hereditary angioedema (HAE) prophylaxis, to BioCryst's portfolio.
The transaction represents a premium of approximately 53% over Astria's closing share price on October 13, 2025, and BioCryst anticipates remaining profitable (non-GAAP) and cash flow positive post-transaction.
As of September 30, 2025, Astria reported preliminary and unaudited cash, cash equivalents, and short-term investments of approximately $227.7 million.

Oct 14, 2025, 11:12 AM

8-K

Astria Therapeutics Initiates Phase 3 ORBIT-EXPANSE Trial for Navenibart

ATXS

New Projects/Investments

Astria Therapeutics has initiated the Phase 3 ORBIT-EXPANSE long-term trial for its lead program, navenibart, in people with hereditary angioedema (HAE).
Navenibart is an investigational monoclonal antibody inhibitor of plasma kallikrein designed for rapid and sustained HAE attack prevention, administered subcutaneously every 3 or 6 months.
The ORBIT-EXPANSE trial is part of a broader Phase 3 program, which also includes the ALPHA-ORBIT trial, both designed to support global registration for navenibart.

Oct 8, 2025, 12:00 PM

Press Release

Astria Therapeutics expands Phase 3 ALPHA-ORBIT trial to EU

ATXS

New Projects/Investments

Astria Therapeutics has initiated the opening of clinical centers in the European Union (EU) for its Phase 3 ALPHA-ORBIT trial of navenibart.
Navenibart is an investigational monoclonal antibody designed to treat hereditary angioedema (HAE), with potential for administration every 3 or 6 months.
The trial, authorized by the European Medicines Agency (EMA), plans to activate 32 centers across 10 EU countries and aims to enroll up to 135 adults and 10 adolescents with HAE Type 1 or 2.

Oct 2, 2025, 8:07 PM

Press Release

Astria Therapeutics Initiates EU Patient Enrollment for Phase III ALPHA-ORBIT Trial

ATXS

New Projects/Investments

Astria Therapeutics has commenced patient enrollment in the European Union for its Phase III ALPHA-ORBIT trial of navenibart, an investigational treatment for hereditary angioedema (HAE).
The trial is expanding to 10 EU countries, including Bulgaria, Czech Republic, France, Germany, Hungary, Italy, Netherlands, Poland, Portugal, and Spain, adding to existing sites in other global regions.
Navenibart is a plasma kallikrein monoclonal inhibitor being developed for HAE, with a potential dosing regimen of every 3 and 6 months.
The ALPHA-ORBIT trial is designed to assess the efficacy and safety of navenibart in up to 135 adults and 10 adolescents with HAE type 1 or 2.

Oct 2, 2025, 8:01 PM

Press Release

Astria Therapeutics Initiates EU Enrollment for ALPHA-ORBIT Phase 3 Study

ATXS

New Projects/Investments

Astria Therapeutics has begun enrolling Hereditary Angioedema (HAE) patients in the European Union for its ALPHA-ORBIT Phase 3 study of navenibart.
The ALPHA-ORBIT study is a global, randomized, double-blind, placebo-controlled Phase 3 trial evaluating the efficacy and safety of navenibart, an experimental monoclonal antibody inhibitor of plasma kallikrein, for HAE.
Navenibart is designed for subcutaneous administration every 3 or 6 months.
The European Medicines Agency (EMA) approval facilitates the activation of 32 sites across 10 EU countries, including Bulgaria, Czech Republic, France, Germany, Hungary, Italy, Netherlands, Poland, Portugal, and Spain.